Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

TD Cowen analyst Ritu Baral maintained a Hold rating on Sarepta Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $20.08. According to TipRanks.com, Baral ...

Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT ...

Intellia Therapeutics plunged 29% on safety concerns but rebounded as the full story emerged, showing the value of patience.

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

Fintel reports that on July 21, 2025, Needham downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Hold to ...

Fintel reports that on July 21, 2025, Leerink Swann downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...